14-day Premium Trial Subscription Sign Up For FreeGet Free

Amarin Corporation PLC Stock Forecast NASDAQ:AMRN

$3.56 (-2.20%)

Volume: 6M

Closed: Nov 29, 2021

Hollow Logo Score: -8.146

Amarin Corporation PLC Stock Forecast

$3.56 (-2.20%)

Volume: 6M

Closed: Nov 29, 2021

Score Hollow Logo -8.146

Amarin Corporation PLC Stock Forecast NASDAQ:AMRN

Price Target and Analyst Ratings

Most Recent Rating

On Sep 26, 2021 "SVB Leerink" gave "$12.00" rating for AMRN. The price target was changed from $5.40 to 0.7%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-09-26 $12.00 Reiterated by SVB Leerink $5.40 $5.40→0.7%
2021-09-09 $12.00 Initiated by SVB Leerink $5.27 $5.30+2.9%
2021-08-09 $10.00 Reiterated by HC Wainwright $4.85 $4.93+1.4%
2021-06-11 $10.00 Reiterated by Cantor Fitzgerald $4.95 $4.53+4.0%
2021-06-11 Buy Reiterated by Cantor Fitzgerald $4.95 $10.00
2021-05-18 Neutral - Sell Reiterated by The Goldman Sachs Group $4.54 $6.00 → $5.00
2021-05-12 Neutral - Sell Downgraded by The Goldman Sachs Group $4.35 $6.00 → $5.00
2021-02-01 Outperform Target Raised by SVB Leerink $8.08 $12.00 → $16.00
2021-02-01 Buy Reiterated by HC Wainwright $8.08
2021-01-08 Overweight Reiterated by Piper Sandler $5.87 $19.00
2020-12-23 Target Lowered by The Goldman Sachs Group $5.13 $8.00 → $6.00
2020-12-07 Target Lowered by Smith Barney Citigroup $5.08 $12.00 → $7.00
2020-12-07 Target Lowered by Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell $5.08 $12.00 → $7.00
2020-09-29 Neutral Initiated by JPMorgan Chase & Co. $4.04
2020-09-28 Outperform Target Raised by SVB Leerink $4.00 $9.00 → $12.00
2020-09-08 Target Lowered by Cantor Fitzgerald $4.35 $35.00 → $15.00
2020-09-03 Hold Target Lowered by Stifel Nicolaus $4.56 $8.00 → $5.00
2020-08-25 Overweight Initiated by Piper Sandler $6.68
2020-08-05 Buy Reiterated by HC Wainwright $6.86
2020-08-04 Hold Reiterated by Stifel Nicolaus $7.03 $8.00
2020-06-16 Hold Reiterated by Stifel Nicolaus $6.89
2020-06-15 Buy Reiterated by Cantor Fitzgerald $6.85 $35.00
2020-06-03 Hold Reiterated by Oppenheimer $6.64
2020-05-05 Outperform Initiated by Northland Securities $7.72 $15.00
2020-05-04 Outperform Target Raised by SVB Leerink $7.62 $7.00 → $9.00
2020-05-04 Buy Target Raised by Aegis $7.62 $9.00 → $11.00
2020-05-01 Buy Target Raised by Citigroup $7.34 $6.00 → $12.00
2020-05-01 Buy Reiterated by HC Wainwright $7.34
2020-04-30 Hold Reiterated by Stifel Nicolaus $7.61 $8.00
2020-04-14 Target Raised by Cowen $6.38 $8.00 → $10.00

AMRN Stock Trend

The stock has broken the wide and falling short-term trend down. Firstly a stronger fallrate is indicated, but false breaks and "sell-off" may occur. However, a further fall is realistic and any reactions back to the breaking point ($3.77) are considered to be a "second chance" to get out. According to the fan-theory $3.33 will represent the new bottom line of the next trend, but it is far too early to say this for certain.

Data

Date Bottom Mid Top
2021-12-01 $3.74 $3.96 $4.18
2021-12-02 $3.72 $3.94 $4.16
2021-12-03 $3.69 $3.91 $4.13
2021-12-06 $3.66 $3.88 $4.10
2021-12-07 $3.64 $3.86 $4.08
2021-12-08 $3.61 $3.83 $4.05
2021-12-09 $3.58 $3.80 $4.02
2021-12-10 $3.56 $3.78 $4.00
2021-12-13 $3.53 $3.75 $3.97
2021-12-14 $3.50 $3.72 $3.94
2021-12-15 $3.48 $3.70 $3.92
2021-12-16 $3.45 $3.67 $3.89
2021-12-17 $3.42 $3.64 $3.86
2021-12-20 $3.40 $3.62 $3.84
2021-12-21 $3.37 $3.59 $3.81
2021-12-22 $3.34 $3.56 $3.78
2021-12-23 $3.32 $3.54 $3.76
2021-12-27 $3.29 $3.51 $3.73
2021-12-28 $3.26 $3.48 $3.70
2021-12-29 $3.24 $3.46 $3.68
2021-12-30 $3.21 $3.43 $3.65
2021-12-31 $3.18 $3.40 $3.62
2022-01-03 $3.16 $3.38 $3.60
2022-01-04 $3.13 $3.35 $3.57
2022-01-05 $3.10 $3.32 $3.54
2022-01-06 $3.08 $3.30 $3.52
2022-01-07 $3.05 $3.27 $3.49
2022-01-10 $3.02 $3.24 $3.46
2022-01-11 $3.00 $3.22 $3.44
2022-01-12 $2.97 $3.19 $3.41

About Amarin Corporation PLC

Amarin  PLC Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company’s lead product includes Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT